Verve Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $13,080 | $6,865 | $6,692 | $5,695 |
Gross Profit | 13,080 | 5,111 | 5,025 | 4,063 |
EBITDA | -54,367 | -55,156 | -57,172 | -55,212 |
EBIT | -56,067 | -56,910 | -58,839 | -56,844 |
Net Income | -50,035 | -50,133 | -49,805 | -48,736 |
Net Change In Cash | 13,080 | 6,865 | 6,692 | 5,695 |
Free Cash Flow | -42,232 | -40,543 | -35,138 | -43,515 |
Cash | 172,560 | 158,709 | 141,490 | 144,200 |
Basic Shares | 86,874 | 84,632 | 84,226 | 83,132 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $32,332 | $11,758 | $1,941 | $0 |
Gross Profit | 32,332 | 6,303 | -4,770 | -3,377 |
EBITDA | -228,660 | -217,669 | -162,883 | -85,532 |
EBIT | -223,124 | -169,594 | -87,067 | |
Net Income | -198,709 | -200,068 | -157,387 | -118,637 |
Net Change In Cash | 32,332 | 11,758 | 1,941 | 0 |
Cost of Revenue | 50,669 | 60,111 | ||
Free Cash Flow | -161,428 | -158,832 | -135,564 | -82,239 |
Cash | 172,560 | 206,180 | 115,412 | 64,330 |
Basic Shares | 84,632 | 64,175 | 54,023 | 48,511 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.58 |
2024-09-30 | -$0.59 |
2024-06-30 | -$0.59 |
2024-03-31 | -$0.59 |
